High-throughput screening of anti-lipidemic agents using PXB-cells, human primary hepatocytes from humanized mice livers : Assessment of lipoproteins by an enzyme-linked immunosolvent assay on apolipoproteins
-
- Tomatsu Sayaka
- Akita Research Institute of Food & Brewing
-
- Takahashi Masaki
- PhoenixBio Co., Ltd.
-
- Toshima Gen
- Skylight Biotech Inc.
-
- Nakagawa Shiho
- Skylight Biotech Inc.
-
- Takahashi Junichiro
- Skylight Biotech Inc.
-
- Miyashita Kazuya
- Immuno-Biological Laboratories Co., Ltd.
-
- Ogura Kazumi
- Immuno-Biological Laboratories Co., Ltd.
-
- Kakuni Masakazu
- PhoenixBio Co., Ltd.
-
- Hata Keishi
- Akita Research Institute of Food & Brewing
書誌事項
- タイトル別名
-
- High-throughput screening of anti-lipidemic agents using PXB-cells®, human primary hepatocytes from humanized mice livers: Assessment of lipoproteins by an enzyme-linked immunosolvent assay on apolipoproteins
- Apolipoprotein assay for assessing lipoprotein in hepatocyte
この論文をさがす
説明
We previously assessed anti-lipidemic activity by evaluating lipoprotein profiles in PXB-cells®, human primary hepatocytes from humanized mice livers, using LipoSEARCH®. This highly sensitive assay system detects low levels of extracellular lipoproteins; however, an increased throughput is needed to simultaneously assay multiple analytes. We herein investigated whether an enzyme-linked immunosolvent assay (ELISA) on apolipoproteins (APO) accurately detects reductions in extracellular lipoprotein levels in PXB-cells treated with fenofibrate as an alternative to LipoSEARCH. These results suggest the applicability of ELISA on APO to the conventional screening of anti-lipidemic activities in a large number of candidates.
収録刊行物
-
- Journal of Biological Macromolecules
-
Journal of Biological Macromolecules 21 (2), 89-92, 2021
日本生物高分子学会